Daunorubicin or Idarubicin

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Janssen Research & Development, LLC, Stichting Hemato-Oncologie voor Volwassenen Nederland

Conditions

Acute Myeloid LeukemiaFLT3-mutated Acute Myeloid LeukemiaLeukemia, Myeloid, Acute

Phase 1

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Active, not recruitingNCT05453903

Janssen Research & Development, LLCLeukemia, Myeloid, Acute

Start: 2022-10-04End: 2027-03-19Updated: 2026-03-12

Phase 2

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Active, not recruitingNCT03591510

Novartis PharmaceuticalsFLT3-mutated Acute Myeloid Leukemia

Start: 2019-03-13End: 2029-05-18Updated: 2026-03-13

Phase 3

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Not yet recruitingNCT07223814

Stichting Hemato-Oncologie voor Volwassenen NederlandAcute Myeloid Leukemia

Start: 2025-12-31End: 2033-12-31Target: 875Updated: 2025-11-03

Related Papers

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Blood2025-11-031 citations

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Blood2025-11-031 citations

Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Blood2025-11-031 citations

Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations

Blood2025-11-031 citations

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations

Blood2024-11-0520 citations

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias

Blood2024-06-2143 citations

Preclinical Efficacy of the Menin-KMT2A Inhibitor JNJ-75276617 in Combination with Venetoclax and Azacitidine in AML

Blood2023-11-023 citations

PB1890: TRIAL IN PROGRESS: A PHASE II STUDY OF MIDOSTAURIN COMBINED WITH INDUCTION/CONSOLIDATION CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN PEDIATRIC PATENTS WITH FLT3-MUTATED ACUTE MYELOID LEUKEMIA

HemaSphere2023-08-01

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML)

Blood2019-11-134 citations